Glaukos Corp cash flow statement
In fiscal 2025, Glaukos Corp's operations generated −$14.8m of cash; it spent $7.7m on capital projects, leaving free cash flow of −$22.5m.
Cash flow statement
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −13 | −7 | −2 | 12 | 26 | 19 | −0 | −23 | 25 | −33 | −58 | −61 | −15 | 48 |
| Depreciation and amortisation | 1 | 4 | 4 | 5 | 5 | 6 | 6 | 29 | 30 | 32 | 34 | 36 | 38 | 42 |
| Stock-based pay | 1 | 2 | 8 | 9 | 18 | 26 | 36 | 46 | 30 | 39 | 44 | 50 | 63 | 83 |
| Capital spending | 1 | 1 | 1 | 6 | 6 | 10 | 5 | 7 | 48 | 30 | 20 | 6 | 8 | 12 |
| Free cash flow | −14 | −8 | −3 | 6 | 20 | 9 | −5 | −30 | −23 | −63 | −78 | −68 | −22 | 36 |
| Free cash flow after stock pay | −16 | −10 | −11 | −3 | 2 | −17 | −41 | −76 | −53 | −102 | −122 | −118 | −86 | −47 |
| Share buybacks | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | −19 | 7 | −10 | 7 | −13 | 15 | 39 |
| Depreciation and amortisation | 9 | 8 | 9 | 9 | 12 | 12 | 9 | 9 |
| Stock-based pay | 13 | 13 | 18 | 15 | 17 | 19 | 29 | 18 |
| Capital spending | 2 | 2 | 1 | 2 | 3 | 4 | 3 | 2 |
| Free cash flow | −1 | −20 | 6 | −12 | 4 | −16 | 12 | 36 |
| Free cash flow after stock pay | −15 | −33 | −12 | −27 | −13 | −36 | −17 | 19 |
Compare with peers
- Transmedics Group, Inc. cash flow
- Novocure Ltd cash flow
- Myriad Genetics Inc cash flow
- Bioventus Inc. cash flow
- Irhythm Holdings, Inc. cash flow
Head to head: GKOS vs TMDXGKOS vs NVCRGKOS vs MYGNBVS vs GKOS
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies